Biotech ETFs Slip After Novavax Cuts 2022 Guidance

Biotechnology sector-related exchange traded funds retreated with Novavax Inc. (NasdaqGS: NVAX), plunging after the vaccine developer cut its 2022 revenue guidance in half. On Tuesday, the iShares Genomics Immunology and Healthcare ETF (IDNA) fell 4.1%, ETFMG Treatments Testing and Advancements ETF (GERM) dropped 4.3%, SPDR S&P Biotech ETF (XBI) decreased 3.4%, and ALPS Medical Breakthroughs [...] The post Biotech ETFs Slip After Novavax Cuts 2022 Guidance appeared first on ETF Trends .